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Abstract
Background: Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor in men and the seventh
in women and understanding the molecular mechanisms of HCC and establishing more effective therapies are
critical and urgent issues. Our objective was to study the expression of ferroportin in hepatocellular carcinoma
(HCC) tissue samples and the relationship between ferroportin expression and HCC characteristics.
Methods: Sixty HCC tissues and their corresponding para-cancer liver tissues (PCLT) were obtained from sixty HCC
patients who had undergone hepatectomy in the Second Xiangya Hospital of Central South University. Ten normal
liver tissue samples were also obtained as a control. Immunohistochemistry (IHC) was performed to analyze the
ferroportin expression in HCC, and the relationship between ferroportin expression and HCC clinical pathological
characteristics also was analyzed. For the evaluation of IHC results, the comprehensive scoring criteria were met
according to the staining intensity and the number of positive staining cells. Western blotting was performed to
detect the expression level of ferroportin in HCC cell lines.
Results: Ferroportin expression in HCC tissue was significantly lower compared to PCLT and normal liver tissue
(P <0.05). Moreover, ferroportin expression was related to liver cancer cell de-differentiation, the severity degree in
TNM staging, Edmondson-Steiner grading, intrahepatic metastasis and portal vein invasion. In addition, high
expression of ferroportin was observed in normal human liver cell lines L02 and HL7702, whereas weak positive
expression and even negative expression of ferroportin were observed in HCC cell lines FOCUS, MHCC-97H,
HepG2 and SMMC-7721. Furthermore, among the four kinds of HCC cell lines, the expression level of ferroportin
was the lowest in MHCC-97H cells.
Conclusions: Ferroportin expression level declines along with the progression of liver cancer, suggesting that the
reduction of ferroportin may serve as an important marker for poor HCC prognosis and as a new therapeutic target.
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Background
Hepatocellular carcinoma (HCC) is the fifth most common
malignant tumor in men and the seventh in women, being
one of the most lethal forms of malignancies with less than
10% survival rate [1]. Globally, there are about 626,000
new HCC cases and nearly 600,000 HCC-related deaths
each year [2,3]. Most HCC occurs in the setting of viral
infection, alcohol abuse, and/or nonalcoholic steatohe-
patitis. Therefore, the prevention of hepatitis B and C
virus transmission as well as the institution of guidelines
to reduce the prevalence of obesity must be the focus
for HCC prevention [4,5]. Therefore, understanding the
molecular mechanisms of HCC and establishing more
effective therapies are critical and urgent issues.
Iron, an essential element for normal cell function, has
been linked to tumor cell growth for a long history in
experimental and clinical literatures [6,7]. High dietary
iron increases the occurrence of cancers in animal
models, while low iron diets inhibit the growth of tumor
xenografts [8-11]. Moreover, modulation of iron-regulatory
proteins can affect the growth of lung tumor xenografts
[12,13]. These findings have promoted the exploration
of agents that deplete iron as anticancer therapies [14-17].
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Ferroportin (ferroportin 1, also termed Ireg1, MTP1 and
SLC40A1) is the only known mammalian export protein
for nonheme iron [18-20]. Ferroportin is a cell surface
protein with 12 predicted transmembrane domains and is
ubiquitously expressed but expressed at high concentra-
tions on duodenal enterocytes, hepatocytes, placenta, and
macrophages [21]. The importance of ferroportin in iron
homeostasis of the body has been demonstrated both
in human and animal studies [22]. There are at least
three mechanisms regulating the level of ferroportin:
transcriptional regulation, translational control, and protein
level when ferroportin interacts directly with the peptide
hormone hepcidin which is secreted by liver, resulting
in ferroportin internalization and proteasome-mediated
degradation [23-25].
The role of ferroportin in cancer has not been exten-
sively studied [26,27]. In 2010, Pinnix and his colleagues
reported that in breast cancer tissue ferroportin protein is
substantially reduced compared to normal human mam-
mary tissue [28]. In a mouse tumor model, transfecting
ferroportin into breast cancer cells significantly reduces
their growth. Moreover, the decrease of ferroportin gene
expression is a good predicative factor for a poor curative
effect in human. In contrast, high ferroportin gene ex-
pression is an extremely favorable cohort to breast
cancer patients.
Now that ferroportin has an important role in breast
cancer, how about HCC? Ferroportin has a high expression
level in liver and hepatocytes, and liver is the pivotal organ
for iron metabolism [18-20,29]. For the reasons above, we
are strongly interested in the role of ferroportin in HCC.
What is its expression level in HCC tissue and cells?
Can we inhibit the growth and metastasis of tumor cells
by ferroportin modulation? The study of ferroportin in
HCC will surely lead to a better understanding of the
genesis and progression mechanism of HCC and provide
new experimental evidence for HCC treatment.
Methods
Sample collecting and grouping
All the human tissue samples were obtained from the
Second Xiangya Hospital of Central South University.
We collected three kinds of samples: 1) For the HCC
group we collected the HCC tissue samples from all
HCC patients who had undergone hepatectomy in the
Second Xiangya Hospital of Central South University
during the years 2007 to 2011. These HCC patients had
never received other therapies such as transcatheter arterial
chemo-embolization, chemotherapy, or radiotherapy. All
specimens had been confirmed by pathological diagnosis
to be primary HCC. 2) For the para-cancer liver tissues
(PCLT) group we took the PCLT that were located more
than 2 cm from the tumor edge that had no necrosis from
the HCC patients’ sample stated above. All these samples
had gone through pathological examination and found to
be free of cancerization and invasion. 3) For the normal
liver tissue group we collected 10 normal liver tissue
samples from patients without viral hepatitis history. All
specimens were collected within half an hour of being
detached from the body. For the use of these clinical
materials for research purposes, prior consent from the
patients and approval from the Ethics Committees of
the Second Xiangya Hospital of Central South University
were obtained. The specimens of the three groups above
were tested by immunohistochemistry (ICH) to show the
expression level of ferroportin.
Clinical characteristics of hepatocellular carcinoma
(HCC) patients
All 60 specimens from the HCC patients have undergone
clinical and pathological diagnosis, and the HCC diagnostic
criteria were met according to the criteria of World Health
Organization. Tumor differentiation degree was classified
by Edmondson-Steiner grading. Liver function was ana-
lyzed according to Child-Pugh score. Tumors were staged
according to the sixth edition Tumor Node Metastasis
(TNM) staging set by Union for International Cancer
Control. The clinical data and pathological material were
recorded. The basic clinical characteristics of HCC patients
are shown in Table 1.
Immunohistochemistry
IHC was performed according to standard protocol.
Paraffin tissue sections were deparaffinized in turpentine
and rehydrated in a descending ethanol series according
to standard protocols. Heat-induced antigen retrieval was
performed in 0.01 mol/L citrate buffer at 100°C for 20
min. Antigen retrieval by enzyme digestion was performed
in 0.1% trypsin at 37°C for 25 min. Sections were then
blocked with serum for 30 min followed by incubation
with rabbit anti-SLC40A1 antibody (Abcam, ab85370)
for 1 to 2 hours at 37°C. After washing, the sections were
Table 1 The clinical characteristics of hepatocellular
carcinoma (HCC) patients (60 cases in all)
Characteristic Number
Age (years) 50.1 ± 8.5
Sex (male/female) 51/9
Etiology (HBV/alcohol/HCV/HBV + HCV/others) 38/5/7/6/4
Potential disease (chronic hepatitis/liver cirrhosis) 9/51
Intrahepatic metastasis (+/−) 12/48
Portal vein invasion (+/−) 11/49
Edmondson-Steiner grading ( I to II/ III to IV) 34/26
TNM staging (I to II/ III to IV) 34/26
AFP (ng/mL) (≤ 400/> 400) 49/11
AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.
Wang et al. European Journal of Medical Research 2013, 18:59 Page 2 of 7
http://www.eurjmedres.com/content/18/1/59
incubated with horseradish peroxidase-goat anti-rabbit
antibody at 37°C for 30 minutes. The peroxidase reaction
was developed with 3, 3-diaminobenzidine (DAB) solution
in DAB buffer substrate. Sections were visualized with
DAB and counterstained with hematoxylin, mounted in
neutral gum and analyzed using a bright field microscope.
A nasopharyngeal carcinoma pathological section was
used as a negative control, and the primary antibody
was substituted with PBS.
For the evaluation of IHC results, the comprehensive
scoring criteria were met according to the staining intensity
and the number of positive staining cells: 1) the scoring
criteria for staining intensity: 0, no staining; 1, weak stain-
ing; 2, modest staining; 3, strong staining; and 2) the
proportion of tumor cell staining: 0, no positive tumor
cells; 1, ≤ 25% positive tumor cells; 2, 25 to 50% positive
tumor cells; 3, 51 to 75% positive tumor cells; 4, >75%
positive tumor cells. The final score was calculated by
adding the tumor staining area and the intensity score.
A final score of 0 was treated as 0, negative expression;
staining scores 1 to 3 were treated as 1, a weak positive
expression; 4 and 5 were regarded as 5, an intermediate
positive expression; and 6 and 7 were regarded as 7, a
strong positive expression. Two pathologists scored all
samples blindly without knowing clinical characteristics.
Cell lines and cell culture
FOCUS, HepG2 and SMMC-7721 are HCC cell lines,
whereas MHCC-97H is a highly metastatic HCC cell line.
L02 and HL7702 are normal human liver cell lines. All the
cells were cultivated in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% fetal bovine serum.
Western blotting analysis
Equal amounts of total extract protein (50 μg) were
separated by 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and blotted with polyvi-
nylidene fluoride (PVDF) membranes. After being blocked
with 5% skim milk at room temperature for 1 hour and
washed, membranes were probed with rabbit-anti-SLC40A1
(ab85370, Abcam, Cambridge, UK) and mouse anti-β-actin
(sc-47724, Santa Cruz, California, USA) at 4°C overnight
and then incubated with anti-mouse or anti-rabbit IgG
antibodies conjugated with horseradish peroxidase. After
final treatment with enhanced chemiluminescence assay
(ECL) reagents (GE Healthcare), samples were exposed
to X-ray film to detect and record relevant protein bands.
Statistical analysis
All statistical analyses were analyzed using SPSS 17.0
software (SPSS Inc, Chicago, IL, USA). The ANOVA
and t-test of independent samples were used to analyze
comparisons of means. All the data were presented as
mean ± S.D. The comparison of count data was analyzed
by nonparametric test. Statistical difference was accepted
at P <0.05.
Results
The expression and location of ferroportin in
hepatocellular carcinoma
In this study, IHC was used to evaluate the expression
level and detect the location of ferroportin in HCC
tissue sections (60 cases) and PCLT sections. The result
demonstrated that ferroportin had two kinds of expression
patterns in normal liver cells: 1) ferroportin showed
obvious brownish black staining in the cytoplasm and
cell membrane among most of the liver cells (Figure 1A),
and 2) in several liver cells ferroportin showed obvious
brown orange staining only in cell membrane (Figure 1B).
These data demonstrated the strong positive expression
of ferroportin was observed in the cytoplasm and cell
membrane of normal liver cells. However, ferroportin
positive staining was not observed in most of HCC tissues,
leaving only a small part with weak positive staining
(Figure 1C, 1D). Statistical analysis showed that the
positive expression rate of ferroportin in normal liver
tissues (10 cases) was 100% (10/10) and average scoring
was 6.38 ± 3.27. For PCLT (60 cases), the positive expres-
sion rate of ferroportin was 91.17% (55/60) and average
scoring was 5.97 ± 3.12. For HCC tissues the positive rate
was 28.3% (17/60) and average scoring was 0.96 ± 0.39
(Table 2).
Ferroportin positive expression rate and positive stain-
ing score in the HCC group were significantly decreased
compared to the PCLT group and the normal liver tissue
group (P <0.05). However, there was no significant differ-
ence in ferroportin positive expression rate and positive
staining score between PCLT group and normal liver tissue
(P >0.05).
The relationship of ferroportin expression and
hepatocellular carcinoma clinical characteristics
There was a negative correlation between ferroportin ex-
pression and TNM staging; in the III to IV stage group,
ferroportin had the highest negative staining rate (n = 21,
80.8%), the lowest modest staining rate (n = 1, 3.8%) and
strong staining (n = 0, 0%). However, in the I to II stage
group, negative staining cases reduced greatly (n = 22,
64.7%) and modest positive staining and strong positive
staining increased to n = 5, 14.7% and n = 22, 64.7%, re-
spectively. The expression level of ferroportin protein
decreased with the increase of TNM (P = 0.008). A similar
relationship was also found between ferroportin expres-
sion and Edmondson-Steiner grading (P = 0.002). In
addition, ferroportin expression was significantly lower
in groups with intrahepatic metastasis and portal vein
invasion than those without (P = 0.007). However, there was
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no significant relationship between ferroportin expression
and alpha-fetoprotein(AFP) level (P = 0.18) (Table 3).
Ferroportin expression level in hepatocellular carcinoma
cell lines
Given that there was a negative relationship between ferro-
portin expression and several HCC clinical characteristics,
what is the situation of ferroportin expression in HCC cell
lines? Can these HCC cell lines act as research tools for
such kind of studies? To this end, we studied the expression
level of ferroportin in HCC cell lines. We utilized immuno-
blotting to test ferroportin expression in four HCC cell
lines (FOCUS, MHCC-97H, HepG2 and SMMC-7721) and
two normal human liver cell lines (L02 and HL7702). The
results demonstrated that high expression of ferroportin
was observed in normal human liver cell lines L02 and
HL7702, while weak positive expression and even negative
expression of ferroportin was observed in HCC cell
lines FOCUS, MHCC-97H, HepG2 and SMMC-7721
(Figure 2A,B). Further, there was a statistically significant
difference between normal human liver cell lines and HCC
cell lines (P <0.01, Figure 2B). Moreover, the expression
level of ferroportin in MHCC-97H cells is lower than in
the other three kinds of HCC cell lines (P <0.05).
Discussion
Iron, as a required element for living organisms plays an
important role in biology. Several processes related to
Figure 1 Immunohistochemistry (IHC) of the ferroportin expression in hepatocellular carcinoma (HCC) tissue sections (100 bp).
A) Normal liver tissue cytoplasm and cell membrane presented positive ferroportin staining. B) Para-cancer liver tissues (PCLT) cytoplasm and cell
membrane presented positive ferroportin staining. C) and D) Ferroportin positive staining has not been found in HCC tissue sections. A brownish
black staining or brown orange staining shows ferroportin positive staining.
Table 2 The positive expression rate of ferroportin in





HCC 60 17 0.96 ± 0.39a
PCLT 60 55 5.97 ± 3.12
Normal liver tissue 10 10 6.38 ± 3.27
aP <0.05. PCLT, para-cancer liver tissues.
Table 3 The relationship between ferroportin expression
and hepatocellular carcinoma (HCC) clinical
characteristics (n (%))
Characteristic Expression level of ferroportin P
0 1 to 3 4 to 5 6 to 7
Intrahepatic metastasis 0.008*
+ 10 (83.3) 2(16.7) 0 (0) 0 (0)
- 33 (68.8) 7(14.6) 6(12.5) 2(4.2)
Portal vein invasion 0.007*
+ 10 (90.9) 1 (9.1) 0 (0) 0 (0)




I to II 22 (64.7) 5 (14.7) 5 (14.7) 2 (5.9)
III to IV 21(80.8) 4 (15.4) 1 (3.8) 0 (0)
TNM staging 0.01*
I to II 22 (64.7) 5 (14.7) 5 (14.7) 2 (5.9)
III to IV 21 (80.8) 4 (15.4) 1 (3.8) 0(0)
AFP (ng/mL) 0.18
≤400 7 (14.3) 24(49) 15 (30.6) 3 (6.1)
>400 1 (9.1) 5(45.5) 4(36.4) 1 (9.1)
*P < 0.05. AFP, alpha-fetoprotein; TNM, tumor node metastasis.
Wang et al. European Journal of Medical Research 2013, 18:59 Page 4 of 7
http://www.eurjmedres.com/content/18/1/59
iron regulation have been found to be altered in cancer.
An iron storage protein, ferritin, stimulates breast cancer
cells through an iron-independent mechanism [30]. A cell
surface receptor responsible for transferrin-mediated
iron uptake, transferrin receptor 1, is found to increase
in many cancers [31,32]. In principle, reduction in iron
export will increase labile iron and affect cancer pheno-
type and outcome.
Ferroportin is a transmembrane protein that transports
iron from the inside of a cell to the outside of it and is
a critical protein for the regulation of systemic iron
homeostasis [33]. In addition, as the only known mechan-
ism for export of intracellular non-heme-associated iron,
stability of ferroportin is regulated by the hormone hepci-
din. Although ferroportin profoundly affects concentrations
of intracellular iron in tissues important for systemic iron
absorption and trafficking [34], ferroportin in the progres-
sion and prognosis of HCC has not been reported. We
demonstrate here that ferroportin expression in HCC tissue
was significantly lower compared to PCLT and normal liver
tissue (P <0.05). Meanwhile, high ferroportin expression
has been identified in a previous breast cancer study [28].
Thus, we infer that ferroportin is a pivotal protein in HCC
and a strong and independent predictor of prognosis
in HCC.
Recent research has suggested that ferroportin-mediated
iron export is controlled by the hormone hepcidin, which
binds ferroportin, causing its internalization and degrad-
ation [35]. Moreover, Rice et al. revealed that hepcidin
served as an inhibitor for ferroportin, leading to the reten-
tion of iron within cells and a reduction in iron levels
within the plasma [35]. Thus, they believe that hepcidin is
the ‘master regulator’ of human iron metabolism. In our
study, two kinds of expression patterns of ferroportin in
normal liver cells were observed. However, ferroportin
positive staining has not been observed in most of the
HCC tissues. Therefore, we infer that the expression of
ferroportin is different in HCC tissues, and ferroportin
may be used as a marker for HCC prognosis and as a new
therapeutic target.
To our knowledge, mutations in the ferroportin gene
can cause an autosomal dominant form of iron overload
known as type IV hemochromatosis or ferroportin disease
[36]. The effects of the mutations are generally not severe
but spectrums of clinical outcomes are seen with different
mutations. Moreover, Beutler et al. have reported that
ferroportin variant is associated with increased ferritin
levels in African-Americans and may play a role in their
propensity to develop iron overload [37]. In addition,
Pinnix and colleagues have shown that ferroportin and
hepcidin are critical proteins for the regulation of systemic
iron homeostasis and they believe that ferroportin is a
pivotal protein in breast biology and a strong and inde-
pendent predictor of prognosis in breast cancer [28].
Moreover, a previous study has demonstrated that the
expression value of ferroportin and hepcidin gene in
breast cancer may be used as guidance for individualized
therapy for breast cancer patients [38]. These finding and
our results reveal that ferroportin may serve as an import-
ant marker for poor HCC prognosis and as new therapeutic
target.
Conclusions
Our research results demonstrate that ferroportin expres-
sion in HCC tissue is significantly lower in comparison to
PCLT and normal liver tissue, and that ferroportin expres-
sion is correlated with the clinical characteristics of HCC.
All these results reveal that ferroportin expression level is
decreased with the progression of liver cancer, suggesting
that a reduction in ferroportin might be an important
marker for poor HCC prognosis.
However, additional investigation is needed to clarify
the role of ferroportin in HCC and its crosstalk with other
proteins. The ferroportin expression in the HCC cell lines
that we have shown above may provide some useful infor-
mation for the in vitro study of the relationship between
Figure 2 The expression level of ferroportin in different cell
lines. A) Western blotting: 1, Normal human liver cell line L02; 2,
FOCUS; 3, HepG2; 4, MHCC-97H; 5, SMMC-7721. βMactin was shown
as the loading control. B) Statistical graph of the expression level of
ferroportin in different cell lines. **The expression difference of ferroportin
between normal human liver cell line and hepatocellular carcinoma
(HCC) cell lines all had statistical significance, P <0.01. *The difference
of ferroportin expression between MHCC-97H and other HCC cell lines
had statistical significance, P <0.05 (for convenience, the single asterisk
has only been shown between MHCC-97H and FOCUS; it is the same
consequence for the comparison between MHCC-97H and
HepG2/ SMMC-7721).
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ferroportin and HCC as well as the underlying mecha-
nisms. Will the growth rate of HCC cell lines change if
we overexpress or knockdown ferroportin? What is the
situation in vivo in an animal model? All in all, a better
understanding of these might be helpful to the prognosis
or therapy of HCC.
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